Physician profile
Gal Marcan
NPI 1932555844
$5,408.83
in general payments reported to CMS, 2019-2025
47 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $406 · 2023: $1,504 · 2024: $1,717 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.80 | 2023-2025 | |
| Lilly USA, LLC | $645.22 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $525.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.45 | 2022-2025 | |
| Amgen INC. | $270.42 | 2022-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $231.95 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.58 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $224.46 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $174.77 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $156.66 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $116.25 | 2022-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Inspire Medical Systems, INC. | $112.34 | 2023-2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.54 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.59 | 2022-2025 | Xifaxan, Trulance |
| Corium, LLC | $94.71 | 2022-2023 | Azstarys, Adlarity |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $86.79 | 2024-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $75.07 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $72.94 | 2023-2025 | Sunosi, Auvelity |
| Scpharmaceuticals INC. | $65.53 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $65.24 | 2023-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $59.79 | 2023-2024 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $53.64 | 2024 | Heplisav-B |
| Edwards Lifesciences Corporation | $49.98 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Horizon Therapeutics Plc | $47.03 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $40.63 | 2023 | |
| Dexcom, INC. | $37.32 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $31.10 | 2024-2025 | Unithroid |
| Endo USA, INC. | $28.04 | 2024 | Xiaflex |
| Idorsia Pharmaceuticals US INC | $27.92 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $27.22 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $26.83 | 2023-2024 | |
| Bard Peripheral Vascular, INC. | $25.74 | 2024 | Venclose Maven Catheter |
| Azurity Pharmaceuticals, INC. | $24.35 | 2025 | Alvesco |
| Biohaven Pharmaceutical Holding Company LTD. | $23.09 | 2022 | |
| Tolmar, INC. | $21.31 | 2024 | |
| Eisai INC. | $20.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.25 | 2023 | Xarelto |
| Agios Pharmaceuticals, INC. | $19.27 | 2025 | Pyrukynd |
| Boston Scientific Corporation | $17.43 | 2024 | |
| Antares Pharma, INC. | $16.95 | 2024 | Xyosted |
| Abiomed | $16.87 | 2025 | |
| Halozyme INC | $16.85 | 2023 | |
| Lundbeck LLC | $16.41 | 2025 | Rexulti |
| Astellas Pharma US INC | $14.20 | 2025 | Veozah |
| Endo Pharmaceuticals INC. | $14.10 | 2022 | |
| Mylan Specialty L.P. | $14.01 | 2024 | Yupelri |
| Avanir Pharmaceuticals, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gal Marcan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.